-
公开(公告)号：US07273963B2
公开(公告)日：2007-09-25
申请号：US11207176
申请日：2005-08-17
IPC分类号： G01N33/00 , A01K67/00 , A01K67/033 , A01K67/027
CPC分类号： A01K67/0275 , A01K67/0271 , A01K2217/05 , A01K2217/075 , A01K2227/105 , A01K2267/0337 , C12N9/6462 , C12N2830/008 , C12Y304/21073
摘要： The present invention features a non-human animal model of malaria, e.g., Plasmodium, particularly Plasmodium falciparum. The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having anti-pathogenic activity against malaria.
摘要翻译： 本发明的特征在于疟疾的非人动物模型，例如疟原虫，特别是恶性疟原虫。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还具有用于鉴定候选治疗剂的方法，例如具有抗疟疾抗病原活性的药剂。
-
2.发明申请Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection 有权具有嵌合人肝脏和易感人类丙型肝炎病毒感染的动物模型公开(公告)号：US20120309032A1
公开(公告)日：2012-12-06
申请号：US13484073
申请日：2012-05-30
IPC分类号： G01N33/566 , C12Q1/52 , C12Q1/18
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。 本发明的动物也可用于评估各种药物的毒性，以及药物在降低血脂中的活性。
-
公开(公告)号：US07498479B2
公开(公告)日：2009-03-03
申请号：US11517941
申请日：2006-09-07
IPC分类号： A01K67/00 , A01K67/033 , A01K67/027 , C12N15/00
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养性病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。 本发明的动物也可用于评估各种药物的毒性，以及药物在降低血脂中的活性。
-
4.发明授权Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection 有权具有嵌合人肝脏并易受人类丙型肝炎病毒感染的动物模型公开(公告)号：US08212106B2
公开(公告)日：2012-07-03
申请号：US12840188
申请日：2010-07-20
IPC分类号： A01K67/027 , G01N33/00
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养性病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。 本发明的动物也可用于评估各种药物的毒性，以及药物在降低血脂中的活性。
-
5.发明授权Animal model having a chimeric human liver and susceptible to human hepatitis C virus infection 有权具有嵌合人肝脏并易受人类丙型肝炎病毒感染的动物模型公开(公告)号：US07781642B2
公开(公告)日：2010-08-24
申请号：US12333002
申请日：2008-12-11
IPC分类号： G01N33/00 , A01K67/027
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养性病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。 本发明的动物也可用于评估各种药物的毒性，以及药物在降低血脂中的活性。
-
6.发明授权公开(公告)号：US08445745B2
公开(公告)日：2013-05-21
申请号：US13484073
申请日：2012-05-30
IPC分类号： G01N33/00 , A01K67/00 , A01K67/033 , A01K67/027
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
-
7.发明申请Animal Model Having a Chimeric Human Liver and Suceptible to Human Hepatitis C Virus Infection 有权具有嵌合人肝脏和易感人类丙型肝炎病毒感染的动物模型公开(公告)号：US20110167507A1
公开(公告)日：2011-07-07
申请号：US12840188
申请日：2010-07-20
IPC分类号： A01K67/027
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养性病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。 本发明的动物也可用于评估各种药物的毒性，以及药物在降低血脂中的活性。
-
公开(公告)号：US07161057B2
公开(公告)日：2007-01-09
申请号：US10243087
申请日：2002-09-12
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection. The animals of the invention are also useful in assessing toxicity of various agents, as well as the activity of agents in decreasing blood lipids.
-
9.发明授权公开(公告)号：US06509514B1
公开(公告)日：2003-01-21
申请号：US09528120
申请日：2000-03-17
IPC分类号： A01K67027
CPC分类号： C12N15/8509 , A01K67/0271 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/03 , A01K2267/0337 , C07K14/765 , C12N9/6424 , C12N15/63
摘要： The present invention features a non-human animal model that is susceptible to infection by human hepatotrophic pathogens, particularly human hepatitis C virus (HCV). The model is based on a non-human, immunocompromised xenogeneic transgenic animal having a human-mouse chimeric liver, where the transgene provides for expression of a urokinase-type plasminogen activator in the liver. The invention also features methods for identifying candidate therapeutic agents, e.g., agents having antiviral activity against HCV infection.
摘要翻译： 本发明的特征在于非人动物模型，其易受人类肝营养性病原体特别是人丙型肝炎病毒（HCV）的感染。 该模型基于具有人 - 小鼠嵌合肝的非人免疫受损的异种转基因动物，其中转基因提供在肝脏中表达尿激酶型纤溶酶原激活物。 本发明还涉及用于鉴定候选治疗剂的方法，例如具有抗HCV感染的抗病毒活性的试剂。
-
公开(公告)号：US20100104555A1
公开(公告)日：2010-04-29
申请号：US12290017
申请日：2008-10-24
IPC分类号： A61K38/17 , A61K38/16 , C07H21/04 , C12N15/63 , C12N1/21 , C12N5/10 , C12N5/06 , C07K16/00 , A61K31/7088 , A61K39/395 , C12Q1/70 , A61P31/12
CPC分类号： A61K39/29 , A61K31/7088 , A61K39/00 , A61K39/12 , A61K2039/505 , C07K14/005 , C07K16/109 , C07K2317/21 , C07K2317/55 , C07K2317/565 , C07K2317/92 , C12N2770/24222 , C12N2770/24234
摘要： The invention relates to modified hepatitis C virus E2 polypeptides that are effective in eliciting the production of cross-neutralizing antibodies against hepatitis C virus. The invention provides modified hepatitis C virus E2 polypeptides, preparations and pharmaceutical compositions containing them, as well as methods for using these modified E2 polypeptides.
摘要翻译： 本发明涉及有效引发产生针对丙型肝炎病毒的交叉中和抗体的改良型丙型肝炎病毒E2多肽。 本发明提供了修饰的丙型肝炎病毒E2多肽，含有它们的制剂和药物组合物，以及使用这些修饰的E2多肽的方法。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.034 秒)